Among sensitive cell lines, Colo201, Colo205, HT29, and LS174T had a BRAF mutation that is known to improve the antitumor effect of a MEK inhibitor in melanoma with a BRAF mutation (Solit et al., 2006). This evidence concerns the gene MAP2K7 and melanoma.